Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 15 | 2022 | 692 | 2.170 |
Why?
|
| Viral Tropism | 8 | 2018 | 50 | 1.630 |
Why?
|
| HIV Envelope Protein gp120 | 6 | 2019 | 130 | 1.300 |
Why?
|
| Macrophages | 9 | 2022 | 1000 | 1.100 |
Why?
|
| Brain | 5 | 2021 | 1487 | 1.060 |
Why?
|
| HIV Infections | 9 | 2022 | 912 | 0.910 |
Why?
|
| CD4 Antigens | 4 | 2018 | 148 | 0.910 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2017 | 137 | 0.910 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 5 | 2018 | 53 | 0.600 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 104 | 0.550 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2009 | 10 | 0.340 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2009 | 14 | 0.330 |
Why?
|
| Phylogeny | 6 | 2022 | 336 | 0.330 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2009 | 33 | 0.330 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 185 | 0.310 |
Why?
|
| T-Lymphocytes | 3 | 2022 | 983 | 0.310 |
Why?
|
| Receptors, CCR5 | 2 | 2018 | 56 | 0.290 |
Why?
|
| Nervous System Autoimmune Disease, Experimental | 1 | 2006 | 2 | 0.270 |
Why?
|
| Encephalomyelitis | 1 | 2006 | 5 | 0.270 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2006 | 9 | 0.270 |
Why?
|
| Naphthalenes | 1 | 2006 | 18 | 0.270 |
Why?
|
| Morpholines | 1 | 2006 | 86 | 0.260 |
Why?
|
| Cannabinoids | 1 | 2006 | 38 | 0.260 |
Why?
|
| Rolipram | 1 | 2005 | 3 | 0.250 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2005 | 27 | 0.250 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2005 | 59 | 0.240 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2005 | 57 | 0.240 |
Why?
|
| Gene Expression | 2 | 2018 | 808 | 0.230 |
Why?
|
| Proviruses | 2 | 2021 | 26 | 0.220 |
Why?
|
| Multiple Sclerosis | 1 | 2006 | 207 | 0.220 |
Why?
|
| Genes, env | 3 | 2021 | 15 | 0.220 |
Why?
|
| HTLV-I Infections | 1 | 2003 | 3 | 0.210 |
Why?
|
| NF-kappa B | 1 | 2005 | 458 | 0.210 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2003 | 71 | 0.200 |
Why?
|
| Tissue Donors | 1 | 2003 | 143 | 0.200 |
Why?
|
| Sequence Analysis, DNA | 4 | 2021 | 393 | 0.180 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2001 | 25 | 0.180 |
Why?
|
| Apoptosis | 1 | 2006 | 1032 | 0.180 |
Why?
|
| HIV Seropositivity | 1 | 2001 | 82 | 0.180 |
Why?
|
| Liver Transplantation | 1 | 2003 | 207 | 0.180 |
Why?
|
| Deltaretrovirus Infections | 1 | 2000 | 1 | 0.180 |
Why?
|
| HIV-2 | 1 | 2000 | 23 | 0.170 |
Why?
|
| Kidney Transplantation | 1 | 2003 | 312 | 0.170 |
Why?
|
| Spleen | 1 | 2021 | 480 | 0.170 |
Why?
|
| Receptors, Virus | 1 | 2018 | 67 | 0.150 |
Why?
|
| Humans | 17 | 2022 | 59282 | 0.150 |
Why?
|
| Viral Load | 1 | 2019 | 219 | 0.150 |
Why?
|
| Molecular Sequence Data | 4 | 2012 | 1949 | 0.150 |
Why?
|
| Blood-Brain Barrier | 1 | 2017 | 81 | 0.140 |
Why?
|
| Virion | 1 | 2017 | 119 | 0.130 |
Why?
|
| Rats, Inbred Lew | 2 | 2006 | 106 | 0.130 |
Why?
|
| Spain | 2 | 2009 | 32 | 0.130 |
Why?
|
| Virus Replication | 1 | 2017 | 304 | 0.130 |
Why?
|
| Genetic Variation | 2 | 2021 | 357 | 0.120 |
Why?
|
| Virus Internalization | 1 | 2015 | 81 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 806 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2015 | 620 | 0.110 |
Why?
|
| Cells, Cultured | 4 | 2015 | 2089 | 0.110 |
Why?
|
| Receptors, HIV | 1 | 2012 | 15 | 0.100 |
Why?
|
| Virus Attachment | 1 | 2012 | 18 | 0.100 |
Why?
|
| Rats | 2 | 2006 | 1909 | 0.100 |
Why?
|
| HIV Antibodies | 3 | 2018 | 133 | 0.100 |
Why?
|
| Adaptation, Biological | 1 | 2012 | 15 | 0.100 |
Why?
|
| Selection, Genetic | 1 | 2012 | 71 | 0.090 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2011 | 8 | 0.090 |
Why?
|
| DNA, Viral | 2 | 2003 | 223 | 0.090 |
Why?
|
| Conserved Sequence | 1 | 2010 | 169 | 0.090 |
Why?
|
| Microsatellite Repeats | 1 | 2009 | 38 | 0.080 |
Why?
|
| Recombination, Genetic | 1 | 2011 | 238 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2009 | 118 | 0.080 |
Why?
|
| Phenotype | 2 | 2011 | 1136 | 0.080 |
Why?
|
| Genetic Association Studies | 1 | 2009 | 113 | 0.080 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2018 | 176 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 262 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2009 | 745 | 0.070 |
Why?
|
| Adult | 4 | 2018 | 15663 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2006 | 46 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2009 | 1051 | 0.070 |
Why?
|
| Benzoxazines | 1 | 2006 | 10 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 2019 | 400 | 0.070 |
Why?
|
| Adoptive Transfer | 1 | 2006 | 147 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 673 | 0.060 |
Why?
|
| Myelin Basic Protein | 1 | 2005 | 21 | 0.060 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 64 | 0.060 |
Why?
|
| Luciferases | 1 | 2005 | 106 | 0.060 |
Why?
|
| Caspases | 1 | 2006 | 166 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2005 | 115 | 0.060 |
Why?
|
| Disease Progression | 1 | 2009 | 1122 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2005 | 190 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2005 | 214 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 1479 | 0.060 |
Why?
|
| Cell Survival | 1 | 2006 | 559 | 0.060 |
Why?
|
| Spinal Cord | 1 | 2005 | 195 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 527 | 0.060 |
Why?
|
| Antibodies, Neutralizing | 2 | 2018 | 177 | 0.060 |
Why?
|
| Transfection | 1 | 2005 | 675 | 0.050 |
Why?
|
| Cell Movement | 1 | 2005 | 428 | 0.050 |
Why?
|
| Paraparesis, Tropical Spastic | 1 | 2003 | 1 | 0.050 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2003 | 5 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2009 | 1920 | 0.050 |
Why?
|
| Meninges | 1 | 2022 | 10 | 0.050 |
Why?
|
| Equatorial Guinea | 1 | 2001 | 1 | 0.050 |
Why?
|
| Amino Acids | 1 | 2022 | 140 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2001 | 25 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2003 | 291 | 0.050 |
Why?
|
| Male | 4 | 2018 | 27727 | 0.040 |
Why?
|
| HTLV-II Antibodies | 1 | 2000 | 1 | 0.040 |
Why?
|
| HTLV-I Antibodies | 1 | 2000 | 2 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2001 | 168 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2000 | 48 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1464 | 0.040 |
Why?
|
| Risk Factors | 1 | 2009 | 4982 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2011 | 523 | 0.040 |
Why?
|
| Female | 3 | 2009 | 30695 | 0.040 |
Why?
|
| Disease Reservoirs | 1 | 2019 | 9 | 0.040 |
Why?
|
| Autopsy | 1 | 2019 | 53 | 0.040 |
Why?
|
| Base Sequence | 1 | 2001 | 1300 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2046 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 34 | 0.040 |
Why?
|
| Animals | 2 | 2006 | 19601 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2018 | 117 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 153 | 0.040 |
Why?
|
| Sex Factors | 1 | 2000 | 935 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2018 | 169 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 639 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 445 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 1968 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1554 | 0.030 |
Why?
|
| Middle Aged | 1 | 2009 | 16310 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 688 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 288 | 0.020 |
Why?
|
| Adolescent | 1 | 2000 | 5822 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 586 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 837 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 1552 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 1140 | 0.020 |
Why?
|
Gonzalez Perez's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(136)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(7)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_